April 30, 2019 | 1-2 p.m. Eastern
The $528 Billion Opportunity
Employers, health plans and consumers have made the rising cost of medications a priority. But when medications aren’t appropriate, effective and safe, the human and dollar costs mount even higher. Research published in 2018 demonstrates the morbidity and mortality related to non-optimized medication use totals $528 billion a year. In this webinar, join two of that study’s co-authors to explore the direct costs adding up to a $528 billion opportunity to reduce overall costs of care and why the authors believe comprehensive medication management integration offers a viable, cost-effective, scalable solution.
May 14, 2019 | 1 – 2 p.m. EST
Acting on the $528B Opportunity: Training to Advance Comprehensive Medication Management in Practice
Comprehensive medication management (CMM) is recommended as a solution to the problem of non-optimized medication use. This systematic approach to medications is a means to significantly improve clinical outcomes and reduce overall health care costs for high-risk patients. This webinar will delve into the need for CMM and implications for pharmacy education and training, as well as how CMM is integrated into team-based care models.
Comprehensive Medication Management
In this webinar, Steve Simenson BPharm, FAPhA, DPNA, CEO and managing partner of Goodrich Pharmacy, Inc. (and former president of the American Pharmacists Association) shares his insights on Goodrich’s successful CMM program. Simenson discusses how Goodrich integrated CMM into the community pharmacy setting and how it has expanded these services beyond the pharmacy doors.
Simenson is joined by Terry McInnis MD, MPH, CPE, FACOEM, president of Blue Thorn Inc. and principal investigator of Get the medications right: a nationwide snapshot of expert practices–Comprehensive medication management in ambulatory/community pharmacy. McInnis offers an overview of comprehensive medication management, explains how it’s different from other medication management approaches, and discusses key findings of the report and their relevance to community pharmacy.